このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Affimed マネジメント

マネジメント基準チェック /34

Affimed'sの CEO はAndreas Harstrickで、 Jan2024年に任命され、の在任期間は 1 年未満です。の年間総報酬は€ 1.14Mで、 34%給与と66%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.5%を直接所有しており、その価値は$ 512.52K 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と9年です。

主要情報

Andreas Harstrick

最高経営責任者

€1.1m

報酬総額

CEO給与比率	34.0%
CEO在任期間	less than a year
CEOの所有権	0.5%
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	9yrs

経営陣の近況

Recent updates

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Jun 11

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

Aug 15

Need To Know: Analysts Just Made A Substantial Cut To Their Affimed N.V. (NASDAQ:AFMD) Estimates

Apr 20

Announcing: Affimed (NASDAQ:AFMD) Stock Increased An Energizing 177% In The Last Three Years

Feb 15

Affimed and Roche collaborate to study AFM24 in solid tumors

Feb 03

Affimed N.V. initiates equity offering

Jan 12

Affimed inks €25M debt financing deal with Silicon Valley Bank

Jan 11

CEO報酬分析

Affimed の収益と比較して、Andreas Harstrick の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-€93m
Dec 31 2023	€1m	€388k	-€106m
Sep 30 2023	n/a	n/a	-€119m
Jun 30 2023	n/a	n/a	-€111m
Mar 31 2023	n/a	n/a	-€101m
Dec 31 2022	€1m	€374k	-€86m
Sep 30 2022	n/a	n/a	-€76m
Jun 30 2022	n/a	n/a	-€76m
Mar 31 2022	n/a	n/a	-€76m
Dec 31 2021	€1m	€368k	-€58m
Sep 30 2021	n/a	n/a	-€49m
Jun 30 2021	n/a	n/a	-€38m
Mar 31 2021	n/a	n/a	-€32m
Dec 31 2020	€567k	€256k	-€41m

報酬と市場: Andreasの総報酬 ($USD 1.22M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Andreasの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Andreas Harstrick (63 yo)

less than a year

在職期間

€1,140,000

報酬

Dr. Andreas Harstrick M.D., has been Chief Medical Officer of Affimed N.V. since March 1, 2020 and serves as its Member of Management Board and serves as its Interim Chief Executive Officer since January 1...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Andreas Harstrick	Interim CEO	less than a year	€1.14m	0.50% € 411.4k
Wolfgang Fischer	MD, COO & Member of Management Board	6.8yrs	€1.26m	0.96% € 787.4k
Denise Mueller	Chief Business Officer & Member of Management Board	3.1yrs	€1.17m	0.59% € 486.2k
Melvyn Little	Founder & Consultant	24.5yrs	データなし	データなし
Michael Wolf	Head of Finance & Administration	9.5yrs	データなし	データなし
Alexander Fudukidis	Head of Investor Relations & Director of Investor Relations	no data	データなし	データなし
Mary Sandin	Vice President of Marketing & Communications	no data	データなし	データなし

6.8yrs

平均在職期間

58.5yo

平均年齢

経験豊富な経営陣: AFMDの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ulrich Grau	Independent Member of Supervisory Board	9yrs	€85.00k	0.13% € 108.2k
Miroslav Ravic	Member of Scientific Advisory Board	no data	データなし	データなし
Thomas Hecht	Independent Chairman of Supervisory Board	17.5yrs	€162.00k	0.25% € 208.5k
Uta Kemmerich-Keil	Independent Member of Supervisory Board	3.1yrs	€139.00k	0.072% € 59.5k
Susanne Becker	Member of Scientific Advisory Board	no data	データなし	データなし
Andreas Engert	Member of Scientific Advisory Board	no data	データなし	データなし
Max Topp	Member of Scientific Advisory Board	no data	データなし	データなし
Christian Hucke	Member of Scientific Advisory Board	no data	データなし	データなし
Anton Hagenbeek	Member of Scientific Advisory Board	no data	データなし	データなし
Franck Morschhauser	Member of Scientific Advisory Board	no data	データなし	データなし
Ulrike Köhl	Member of Scientific Advisory Board	no data	データなし	データなし
Stephen Ansell	Member of Scientific Advisory Board	9.1yrs	データなし	データなし

9.0yrs

平均在職期間

74yo

平均年齢

経験豊富なボード: AFMDの取締役会は経験豊富であると考えられます ( 9年の平均在任期間)。

Affimed マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Affimed N.V., Annual General Meeting, Jun 26, 2024

Affimed N.V. Announces CEO Changes

Affimed N.V. Announces Executive Changes

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. Establishes Scientific Advisory Board

Recent updates

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Affimed N.V. to Report Q1, 2024 Results on Jun 12, 2024

Affimed N.V., Annual General Meeting, Jun 26, 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed N.V. to Report Fiscal Year 2023 Results on Mar 28, 2024

Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer

Affimed N.V. Announces CEO Changes

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic Nk in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (Bv) and Checkpoint Inhibitors (Cpis)

Affimed N.V. Announces Executive Changes

Affimed N.V. to Report Q3, 2023 Results on Nov 14, 2023

Affimed N.V. Presents Preclinical Data Showing That Addition of an Innate Cell Engager to Nk and Car-Nk Cells

Affimed N.V. Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK(R) for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma

Affimed N.V. Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability

The Affimed N.V. (NASDAQ:AFMD) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Affimed N.V. to Report Q2, 2023 Results on Aug 10, 2023

Affimed N.V.(NasdaqGM:AFMD) dropped from Russell 2000 Dynamic Index

New minor risk - Market cap size

Affimed Announces Addition of Constanze Ulmer-Eilfort to Its Supervisory Board

Consensus revenue estimates decrease by 22%

Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Affimed N.V., Annual General Meeting, Jun 21, 2023

Affimed N.V. to Report Q1, 2023 Results on May 23, 2023

Affimed N.V. Announces Abstracts at Annual Meeting of European Hematology Association

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Affimed N.V. Provides Regulatory Update for AFM13

Affimed N.V. Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. to Report Q3, 2022 Results on Nov 15, 2022

Affimed N.V. Announces Presentation of Phase 1/2 Data from Afm13 in Combination with Allogeneic NK Cells and Preclinical Afm28 Data At Ash 2022 Annual Meeting

Affimed downgraded to hold at Stifel as pipeline lacks development clarity

Health Check: How Prudently Does Affimed (NASDAQ:AFMD) Use Debt?

Now 26% undervalued after recent price drop

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed Q2 2022 Earnings Preview

Affimed N.V. to Report Q2, 2022 Results on Aug 11, 2022

Affimed N.V. Establishes Scientific Advisory Board

Affimed: Preparing For Key Inflection Points

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Affimed N.V. Announces Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies At the Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. to Report Q1, 2022 Results on Jun 01, 2022

Affimed N.V. Presents Data on Innate Cell Engagers Afm24 and Afm28 at 19th Meeting of the Society for Natural Immunity

Affimed N.V. Announces Data from the Dose Escalation Phase of the Phase 1/2A Study with the company’s Innate Cell Engager

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Affimed N.V. Presents Findings from the Dose-Escalation Phase of the First-In-Human Study of AFM24 in Patients with EGFR-Positive Solid Tumors

Affimed Stock: 3 Points For The Bulls

Consensus revenue estimates fall by 23%

Affimed N.V. (NASDAQ:AFMD) Analysts Just Cut Their EPS Forecasts Substantially

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Affimed N.V. Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers After Freezing & Thawing

Affimed N.V. Announces Completion of Enrollment in Redirect, the Registration-Directed Study of Afm13 in PTCL

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

Affimed N.V. to Discuss Treatment of Cd30-Positive Lymphoma Patients with Cord Blood-Derived Natural Killer Cells Pre-Complexed with Innate Cell Engager AFM13

Affimed N.V. Initiates Patient Recruitment for A Phase 1/2A Trial of Innate Cell Engager Afm24 in Combination with Roche’S Anti-Pd-L1 Checkpoint Inhibitor Atezolizumab

Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 Study At the University of Texas MD Anderson Cancer Center

Third quarter 2021 earnings released: €0.14 loss per share (vs €0.069 loss in 3Q 2020)

Affimed: Preparing For A Bullish 2022

Second quarter 2021 earnings released: €0.16 loss per share (vs €0.15 loss in 2Q 2020)

Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?

マネジメント基準チェック /34